<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01980472</url>
  </required_header>
  <id_info>
    <org_study_id>GIDO1201</org_study_id>
    <nct_id>NCT01980472</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients</brief_title>
  <official_title>Phase II Trial of Geriatric Evaluation as Selection Criteria and Predictive Factor of Safety in Elderly Patients (≥ 70 Years) With Non-small Cell Lung Cancer (NSCLC)That Can be Treated With Bevacizumab, Carboplatin and Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo de Investigación y Divulgación Oncológica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo de Investigación y Divulgación Oncológica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II Study of an adapted chemotherapy regimen plus bevacizumab in elderly non-small&#xD;
      cell lung cancer patients selected by geriatric assessment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CRITERIOS INCLUSION&#xD;
&#xD;
        -  Written informed consent confirming that the patient understands the study objective and&#xD;
           the procedures required.&#xD;
&#xD;
        -  Patients must be able to accomplish with the study protocol.&#xD;
&#xD;
        -  Men and women ≥70 years old.&#xD;
&#xD;
        -  Histologically or cytologically confirmed diagnosis of non-squamous non-small cell lung&#xD;
           cancer (NSCLC) with EGFR gen mutational status negative or non-determinable.&#xD;
&#xD;
        -  Patients with stage IV disease.&#xD;
&#xD;
        -  Patients who have not received first-line treatment&#xD;
&#xD;
        -  Patients with ECOG performance status 0 or 1.&#xD;
&#xD;
        -  Adequate bone marrow function, defined as:&#xD;
&#xD;
             -  Absolute neutrophil count (ANC) ≥1.500/mm3 or ≥1.5x109/L;&#xD;
&#xD;
             -  Hemoglobin ≥ 9 g/dL.&#xD;
&#xD;
             -  Platelet count ≥ 100.000/mm3.&#xD;
&#xD;
        -  Adequate renal function, defined as:&#xD;
&#xD;
             -  Creatinine clearance ≥ 40 ml/min, according to MDRD formula.&#xD;
&#xD;
             -  Urine dipstick proteinuria &lt;2+. If urine dipstick for proteinuria ≥2+ 24 hours&#xD;
                urine must be collected within 24 hours, and proteins must be less than 1 g.&#xD;
&#xD;
        -  Fertile males must use an effective contraceptive method (error rate per year &lt;1%)&#xD;
           during the trial and until 6 months after the last study treatment dose, such as sexual&#xD;
           abstinence, previous vasectomy and/or having a partner using any of following methods:&#xD;
           implantables, injections, combined oral contraceptives and/or intrauterine device&#xD;
           (hormonal only).&#xD;
&#xD;
      CRITERIOS EXCLUSION&#xD;
&#xD;
        -  Previous chemotherapy for advanced NSCLC.&#xD;
&#xD;
        -  History of haemoptysis grade ≥ 2 (defined as at least 2.5 mL of bright red blood) in the&#xD;
           3 months before inclusion.&#xD;
&#xD;
        -  Major surgery (including open biopsy), significant traumatic injuries in the 28 days&#xD;
           before inclusion or anticipation of the need of major surgical procedure during the&#xD;
           treatment period&#xD;
&#xD;
        -  Minor surgery, including permanent catheter insertion, in the 24 hours before&#xD;
           bevacizumab infusion.&#xD;
&#xD;
        -  Untreated brain metastases. Patients with CNS metastases treated with radiotherapy or&#xD;
           surgery may be included if there is no evidence of progression after treatment&#xD;
&#xD;
        -  Radiological evidence of a tumor that invades or is adjacent to a main blood vessel&#xD;
           (e.g. lung artery or superior cava venous).&#xD;
&#xD;
        -  Radiotherapy, in any lesion and for any reason, within 28 days before inclusion.&#xD;
           Palliative radiotherapy for bone lesions within 14 days before inclusion is allowed.&#xD;
&#xD;
        -  Treatment with aspirin (&gt;325 mg/day) or clopidogrel (&gt;75 mg/day) within 10 days prior to&#xD;
           bevacizumab first dose. Use of full dose of oral or parenteral anticoagulants or&#xD;
           thrombolytic agents in therapeutic doses. Prophylactic use of anticoagulant therapy is&#xD;
           allowed.&#xD;
&#xD;
        -  Uncontrolled hypertension (systolic BP &gt;140 mmHg, diastolic BP &gt;90mmHg) in the 28 days&#xD;
           previous to inclusion or history of hypertensive crisis, or hypertensive encephalopathy.&#xD;
&#xD;
        -  Clinically significant cardiovascular disease (i.e. cerebrovascular accident (CVA),&#xD;
           myocardial infarction within 6 months prior to inclusion, unstable angina, congestive&#xD;
           cardiac insufficiency NYHA ≥ II, left ventricular ejection fraction (LVEF) &lt;50% or&#xD;
           serious cardiac arrhytmia), not responding to treatment or that can interfere with trial&#xD;
           treatment administration.&#xD;
&#xD;
        -  Not healed wounds, active peptic ulcer or untreated bone fracture.&#xD;
&#xD;
        -  Hypersensibility to any of the active ingredients of the study treatment (bevacizumab,&#xD;
           carboplatine and paclitaxel) or any of its excipients.&#xD;
&#xD;
        -  Serious cognitive impairment that limits the patient to understand and answer the study&#xD;
           questionnaires.&#xD;
&#xD;
        -  Inability to comply with the study protocol and/or follow-up procedures due to&#xD;
           psychological, familiar, social or geographical problems&#xD;
&#xD;
        -  Patients with an ADL score &lt;5 at the screening.&#xD;
&#xD;
        -  Patients with dementia: 9-12 points in the Folstein MMS at the screening.&#xD;
&#xD;
        -  Patients accomplishing fragility Balducci criteria at the screening:&#xD;
&#xD;
             -  Age ≥ 85 years old&#xD;
&#xD;
             -  Dependence in 1 or more ADL&#xD;
&#xD;
             -  &gt;3 comorbilities&#xD;
&#xD;
             -  &gt;1 geriatric syndrome&#xD;
&#xD;
      OBJETIVOS&#xD;
&#xD;
      To assess the toxicity of the treatment in elderly patients (≥70 years) with NSC lung cancer&#xD;
      who meet inclusion criteria for bevacizumab and selected based on a geriatric evaluation.&#xD;
&#xD;
      Determine predictive factors of toxicity in the elderly population (≥70 years). Determine&#xD;
      objective response rate Determine disease control rate Determine progression free survival&#xD;
      Determine overall survival Determine safety of the treatment combination&#xD;
&#xD;
      VARIABLES&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      Rate of grade 3-4 neutropenia defined according to National Cancer Institute Common&#xD;
      Terminology Criteria version 4.0 (NCI-CTC v4.0).&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  Items of the Comprehensive Geriatric Assessment (CGA) scale as predictive factors for&#xD;
           toxicity end-points.&#xD;
&#xD;
        -  Objective response according to the Response Evaluation Criteria In Solid Tumors (RECIST&#xD;
           v1.1).&#xD;
&#xD;
        -  Progression-free survival.&#xD;
&#xD;
        -  Overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Chemotherapy Regimen Plus Bevacizumab</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of grade 3-4 neutropenia defined according to National Cancer Institute Common Terminology Criteria version 4.0 (NCI-CTC v4.0)</measure>
    <time_frame>participants will be followed for the duration of the study, around 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma VEGF</measure>
    <time_frame>participants will be followed for the duration of the study, around 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response and Stable disease according to RECIST</measure>
    <time_frame>participants will be followed for the duration of the study, around 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival and overall survival</measure>
    <time_frame>participants will be followed for the duration of the study, around 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>bevacizumab, carboplatin and paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bevacizumab, carboplatin and paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab, carboplatin and paclitaxel</intervention_name>
    <description>4-6 initial cycles of bevacizumab, carboplatin and paclitaxel bevacizumab until progression or toxicity</description>
    <arm_group_label>bevacizumab, carboplatin and paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent confirming that the patient understands the study objective&#xD;
             and the procedures required.&#xD;
&#xD;
          -  Patients must be able to accomplish with the study protocol.&#xD;
&#xD;
          -  Men and women ≥70 years old.&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of non-squamous non-small cell&#xD;
             lung cancer (NSCLC) with EGFR gen mutational status negative or non-determinable.&#xD;
&#xD;
          -  Patients with stage IV disease.&#xD;
&#xD;
          -  Patients who have not received first-line treatment&#xD;
&#xD;
          -  Patients with ECOG performance status 0 or 1.&#xD;
&#xD;
          -  Adequate bone marrow function, defined as:&#xD;
&#xD;
        Absolute neutrophil count (ANC) ≥1.500/mm3 or ≥1.5x109/L; Hemoglobin ≥ 9 g/dL. Platelet&#xD;
        count ≥ 100.000/mm3. • Adequate renal function, defined as: Creatinine clearance ≥ 40&#xD;
        ml/min, according to MDRD formula. Urine dipstick proteinuria &lt;2+. If urine dipstick for&#xD;
        proteinuria ≥2+ 24 hours urine must be collected within 24 hours, and proteins must be less&#xD;
        than 1 g.&#xD;
&#xD;
        • Fertile males must use an effective contraceptive method (error rate per year &lt;1%) during&#xD;
        the trial and until 6 months after the last study treatment dose, such as sexual&#xD;
        abstinence, previous vasectomy and/or having a partner using any of following methods:&#xD;
        implantables, injections, combined oral contraceptives and/or intrauterine device (hormonal&#xD;
        only).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous chemotherapy for advanced NSCLC.&#xD;
&#xD;
          -  History of haemoptysis grade ≥ 2 (defined as at least 2.5 mL of bright red blood) in&#xD;
             the 3 months before inclusion.&#xD;
&#xD;
          -  Major surgery (including open biopsy), significant traumatic injuries in the 28 days&#xD;
             before inclusion or anticipation of the need of major surgical procedure during the&#xD;
             treatment period&#xD;
&#xD;
          -  Minor surgery, including permanent catheter insertion, in the 24 hours before&#xD;
             bevacizumab infusion.&#xD;
&#xD;
          -  Untreated brain metastases. Patients with CNS metastases treated with radiotherapy or&#xD;
             surgery may be included if there is no evidence of progression after treatment&#xD;
&#xD;
          -  Radiological evidence of a tumor that invades or is adjacent to a main blood vessel&#xD;
             (e.g. lung artery or superior cava venous).&#xD;
&#xD;
          -  Radiotherapy, in any lesion and for any reason, within 28 days before inclusion.&#xD;
             Palliative radiotherapy for bone lesions within 14 days before inclusion is allowed.&#xD;
&#xD;
          -  Treatment with aspirin (&gt;325 mg/day) or clopidogrel (&gt;75 mg/day) within 10 days prior&#xD;
             to bevacizumab first dose. Use of full dose of oral or parenteral anticoagulants or&#xD;
             thrombolytic agents in therapeutic doses. Prophylactic use of anticoagulant therapy is&#xD;
             allowed.&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic BP &gt;140 mmHg, diastolic BP &gt;90mmHg) in the 28 days&#xD;
             previous to inclusion or history of hypertensive crisis , or hypertensive&#xD;
             encephalopathy.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (i.e. cerebrovascular accident (CVA),&#xD;
             myocardial infarction within 6 months prior to inclusion, unstable angina, congestive&#xD;
             cardiac insufficiency NYHA ≥ II, left ventricular ejection fraction (LVEF) &lt;50% or&#xD;
             serious cardiac arrhythmia), not responding to treatment or that can interfere with&#xD;
             trial treatment administration.&#xD;
&#xD;
          -  Not healed wounds, active peptic ulcer or untreated bone fracture.&#xD;
&#xD;
          -  Hypersensibility to any of the active ingredients of the study treatment (bevacizumab,&#xD;
             carboplatine and paclitaxel) or any of its excipients.&#xD;
&#xD;
          -  Serious cognitive impairment that limits the patient to understand and answer the&#xD;
             study questionnaires.&#xD;
&#xD;
          -  Inability to comply with the study protocol and/or follow-up procedures due to&#xD;
             psychological, familiar, social or geographical problems&#xD;
&#xD;
          -  Patients with an ADL score &lt;5 at the screening.&#xD;
&#xD;
          -  Patients with dementia: 9-12 points in the Folstein MMS at the screening.&#xD;
&#xD;
          -  Patients accomplishing fragility Balducci criteria at the screening:&#xD;
&#xD;
        Age ≥ 85 years old Dependence in 1 or more ADL &gt;3 comorbidities &gt;1 geriatric syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Juan Vidal, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grup d'investigació i divulgació en oncologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Virgen de los Lirios</name>
      <address>
        <city>Alcoy</city>
        <state>Comunidad Valenciana</state>
        <zip>03804</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Castellón</name>
      <address>
        <city>Castellón</city>
        <state>Comunidad Valenciana</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Elda</name>
      <address>
        <city>Elda</city>
        <state>Comunidad Valenciana</state>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Manises</name>
      <address>
        <city>Manises</city>
        <state>Comunidad Valenciana</state>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sagunto</name>
      <address>
        <city>Sagunto</city>
        <state>Comunidad Valenciana</state>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan</name>
      <address>
        <city>San Juan</city>
        <state>Comunidad Valenciana</state>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital U. y P. La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Lluis Alcanyis</name>
      <address>
        <city>Xátiva</city>
        <state>Comunidad Valenciana</state>
        <zip>46800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://gido.es/</url>
    <description>web of Sponsor</description>
  </link>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>October 14, 2013</study_first_submitted>
  <study_first_submitted_qc>November 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2013</study_first_posted>
  <last_update_submitted>February 24, 2017</last_update_submitted>
  <last_update_submitted_qc>February 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>January 23, 2018</submitted>
    <submission_canceled>August 27, 2018</submission_canceled>
    <submitted>August 27, 2018</submitted>
    <returned>February 1, 2019</returned>
    <submitted>February 4, 2019</submitted>
    <returned>May 6, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

